While treatment with GM-CSF is mainly used for cancer patients to overcome chemotherapeutic neutropenia and marrow damage, plenty of studies successfully use it in anti-cancer vaccines to increase the anti-tumor immune response [53]. Here, CSF2 is linked to neutropenia.